Argenx

This study tested two different ways of giving the drug efgartigimod to people with generalized myasthenia gravis, a condition that causes muscle weakness. One group received the drug continuously, while the other got it in cycles. The goal was to see which schedule works better …

This phase 2 trial tests an experimental drug called ARGX-117 in 54 adults with multifocal motor neuropathy (MMN), a condition that causes muscle weakness. Participants receive either ARGX-117 or a placebo by IV, and researchers check if the drug can safely delay the need for sta…

This study tested whether adults with CIDP, a nerve disorder causing weakness and numbness, could safely switch from regular intravenous immunoglobulin (IVIg) infusions to a new injectable drug called efgartigimod PH20 SC. Twenty-three participants who were stable on IVIg were gi…

This phase 3 trial tested the long-term safety and effectiveness of efgartigimod, an IV drug, in 101 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants received efgartigimod infusions over 52 w…

This study looked at the long-term safety of efgartigimod in 24 adults with primary Sjögren's syndrome who had already completed a prior trial. Efgartigimod works by lowering certain antibodies that may drive the disease. The main goal was to track side effects over 48 weeks, wit…

This study tested the long-term safety of efgartigimod injections in 184 people with generalized myasthenia gravis, a chronic disease that causes muscle weakness. Participants received repeated treatment cycles over time. The goal was to see if the drug is safe and tolerable when…

This phase 2 study tested the drug efgartigimod in 73 Chinese patients with active lupus nephritis, a serious kidney complication of lupus. Participants received either the drug or a placebo by IV infusion over 24 weeks. The main goal was to see if the drug could reduce protein i…

This study tested a drug called efgartigimod in 98 adults with moderate to severe bullous pemphigoid, a condition causing painful blisters and itching. The goal was to see if the drug could control the disease and allow patients to stop taking steroids. The trial was split into t…

This completed phase 1 trial tested the safety of ARGX-213 in 88 healthy adults aged 18 to 65. Participants received either the drug or a placebo, and researchers monitored side effects, drug levels in the blood, and immune responses over up to 21 weeks. The study aims to underst…

This completed Phase 1 trial tested a single dose of ARGX-109 in 40 healthy adults to see if it is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo. The study lasted about 20 weeks and focused on side effects and drug…